Canadian academy of sport and exercise medicine position statement: Athletes at high altitude

Clinical Journal of Sport Medicine

Volumn 24, Issue 2, 2014, Pages 120-127

  Koehle, Michael S ^a,d   Cheng, Ivy ^b,c   Sporer, Benjamin ^d,e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e CANADIAN SPORT INSTITUTE PACIFIC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; DEXAMETHASONE; GINKGO BILOBA EXTRACT; IBUPROFEN; NIFEDIPINE; SALMETEROL; TADALAFIL; IRON;

ACCLIMATIZATION; ADAPTATION; ALTITUDE; ALTITUDE DISEASE; ARTICLE; ATHLETE; COMPETITION; DRUG USE; EVIDENCE BASED PRACTICE; EXERCISE; GINKGO BILOBA; HUMAN; HYDRATION; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL HISTORY; NUTRITION; PRIORITY JOURNAL; SLEEP; TRAVEL; ULTRAVIOLET RADIATION; ADVERSE EFFECTS; ALTITUDE SICKNESS; ATHLETIC PERFORMANCE; BODY WATER; CANADA; EVIDENCE BASED MEDICINE; IMMUNE SYSTEM; MEAN CORPUSCULAR VOLUME; MEDICAL SOCIETY; PHYSIOLOGY; PROCEDURES; RADIATION RESPONSE; RESPIRATORY FUNCTION; SPORTS MEDICINE;

ACCLIMATIZATION; ALTITUDE; ALTITUDE SICKNESS; ATHLETIC PERFORMANCE; BODY WATER; CANADA; ERYTHROCYTE INDICES; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNE SYSTEM; IRON; PHYSICAL CONDITIONING, HUMAN; RESPIRATORY PHYSIOLOGICAL PHENOMENA; SLEEP; SOCIETIES, MEDICAL; SPORTS MEDICINE; ULTRAVIOLET RAYS;

EID: 84896726916     PISSN: 1050642X     EISSN: 15363724     Source Type: Journal    
DOI: 10.1097/JSM.0000000000000024     Document Type: Article

References (78)

1. Bärtsch P, Saltin B, Dvorak J. Consensus statement on playing football at different altitude. Scand J Med Sci Sports. 2008;18(suppl 1):96-99.
2. Fulco CS, Beidleman BA, Muza SR. Effectiveness of pre-acclimatization strategies for high altitude exposure. Exerc Sport Sci Rev. 2013;41: 55-63.
3. Wilber RL, Stray-Gundersen J, Levine BD. Effect of hypoxic "dose" on physiological responses and sea-level performance. Med Sci Sports Exerc. 2007;39:1590-1599.
4. Richard NA, Koehle MS. Differences in cardio-ventilatory responses to hypobaric and normobaric hypoxia: a review. Aviat Space Environ Med. 2012;83:677-684.
5. Loeppky JA, Icenogle MV, Maes D, et al. Body temperature, autonomic responses, and acute mountain sickness. High Alt Med Biol. 2003;4:367-373.
6. Loeppky JA, Icenogle M, Scotto P, et al. Ventilation during simulated altitude, normobaric hypoxia and normoxic hypobaria. Respir Physiol. 1997;107:231-239.
7. Savourey G, Launay JC, Besnard Y, et al. Normo or hypobaric hypoxic tests: propositions for the determination of the individual susceptibility to altitude illnesses. Eur J Appl Physiol. 2007;100:193-205.
8. Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society consensus guidelines for the prevention and treatment of acute altitude illness. Wilderness Environ Med. 2010;21:146-155.
9. Barry PW, Pollard AJ. Altitude illness. BMJ. 2003;326:915-919.
10. Koehle MS. Exercise at the extremes of cold and altitude. In: Brukner P, Khan K, eds. Clinical Sports Medicine. North Ryde, Australia: McGraw- Hill; 2011:1146-1155.
11. Rupert JL, Koehle MS. Evidence for a genetic basis for altitude-related illness. High Alt Med Biol. 2006;7:150-167.
12. Swenson ER, MacDonald A, Vatheuer M, et al. Acute mountain sickness is not altered by a high carbohydrate diet nor associated with elevated circulating cytokines. Aviat Space Environ Med. 1997;68:499-503.
13. Oliver SJ, Golja P, Macdonald JH. Carbohydrate supplementation and exercise performance at high altitude: a randomized controlled trial. High Alt Med Biol. 2012;13:22-31.
14. Maggiorini M, Brunner-La Rocca HP, Peth S, et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med. 2006;145:497-506.
15. Siebenmann C, Bloch KE, Lundby C, et al. Dexamethasone improves maximal exercise capacity of individuals susceptible to high altitude pulmonary edema at 4559 m. High Alt Med Biol. 2011;12:169-177.
16. Maggiorini M. Prevention and treatment of high-altitude pulmonary edema. Prog Cardiovasc Dis. 2010;52:500-506.
17. Gertsch JH, Lipman GS, Holck PS, et al. Prospective, double-blind, randomized, placebo-controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: the Headache Evaluation at Altitude Trial (HEAT). Wilderness Environ Med. 2010;21:236-243.
18. Raffestin B, Denjean A, Legrand A, et al. Effects of nifedipine on responses to exercise in normal subjects. J Appl Physiol. 1985;58: 702-709.
19. Chick TW, Halperin AK, Jackson JE, et al. The effect of nifedipine on cardiopulmonary responses during exercise in normal subjects. Chest. 1986;89:641-646.
20. Sartori C, Allemann Y, Duplain H, et al. Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med. 2002;346:1631-1636.
21. Sporer BC, Sheel AW, McKenzie DC. Dose response of inhaled salbutamol on exercise performance and urine concentrations. Med Sci Sports Exerc. 2008;40:149-157.
22. McKenzie DC, Fitch KD. The asthmatic athlete: inhaled Beta-2 agonists, sport performance, and doping. Clin J Sport Med. 2011;21:46-50.
23. Ghofrani HA, Reichenberger F, Kohstall MG, et al. Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. Ann Intern Med. 2004;141:169-177.
24. Fischler M, Maggiorini M, Dorschner L, et al. Dexamethasone but not tadalafil improves exercise capacity in adults prone to high-altitude pulmonary edema. Am J Respir Crit Care Med. 2009;180:346-352.
25. Sliney DH. Ocular injury due to light toxicity. Int Ophthalmol Clin. 1988;28:246-250.
26. Moehrle M, Heinrich L, Schmid A, et al. Extreme UV exposure of professional cyclists. Dermatology. 2000;201:44-45.
27. Moehrle M. Ultraviolet exposure in the Ironman triathlon. Med Sci Sports Exerc. 2001;33:1385-1386.
28. Moehrle M, Dennenmoser B, Garbe C. Continuous long-term monitoring of UV radiation in professional mountain guides reveals extremely high exposure. Int J Cancer. 2003;103:775-778.
29. Blumthaler M, Ambach W, Rehwald W. Solar UV-A and UV-B radiation fluxes at two Alpine stations at different altitudes. Theor Appl Climatol. 1992;46:39-44.
30. Moehrle M, Garbe C. Does mountaineering increase the incidence of cutaneous melanoma? A hypothesis based on cancer registry data. Dermatology. 1999;199:201-203.
31. Moehrle M, Dennenmoser B, Schlagenhauff B, et al. High prevalence of seborrhoeic dermatitis on the face and scalp in mountain guides. Dermatology. 2000;201:146-147.
32. Menter JM, Hollins TD, Sayre RM, et al. Protection against UV photocarcinogenesis by fabric materials. J Am Acad Dermatol. 1994;31:711-716.
33. Davis S, Capjack L, Kerr N, et al. Clothing as protection from ultraviolet radiation: which fabric is most effective? Int J Dermatol. 1997;36: 374-379.
34. Cullen AP. Ozone depletion and solar ultraviolet radiation: ocular effects, a United Nations environment programme perspective. Eye Contact Lens. 2011;37:185-190.
35. Lucas RM. An epidemiological perspective of ultraviolet exposure-public health concerns. Eye Contact Lens. 2011;37:168-175.
36. Maverakis E, Miyamura Y, Bowen MP, et al. Light, including ultraviolet. J Autoimmun. 2010;34:J247-257.
37. Norval M. Effects of solar radiation on the human immune system. J Photochem Photobiol B. 2001;63:28-40.
38. Finlay-Jones JJ, Hart PH. Photoprotection: sunscreens and the immunomodulatory effects of UV irradiation. Mutat Res. 1998;422:155-159.
39. Narayanan DL, Saladi RN, Fox JL. Ultraviolet radiation and skin cancer. Int J Dermatol. 2010;49: 978-986.
40. Bailey DM, Castell LM, Newsholme EA, et al. Continuous and intermittent exposure to the hypoxia of altitude: implications for glutamine metabolism and exercise performance. Br J Sports Med. 2000;34:210-212.
41. Bärtsch P, Dehnert C, Friedmann-Bette B, et al. Intermittent hypoxia at rest for improvement of athletic performance. Scand J Med Sci Sports. 2008;18(suppl 1):50-56.
42. Pedersen BK, Toft AD. Effects of exercise on lymphocytes and cytokines. Br J Sports Med. 2000;34:246-251.
43. Nieman DC, Konrad M, Henson DA, et al. Variance in the acute inflammatory response to prolonged cycling is linked to exercise intensity. J Interferon Cytokine Res. 2012;32:12-17.
44. Nieman DC. Marathon training and immune function. Sports Med. 2007; 37:412-415.
45. Nieman DC. Current perspective on exercise immunology. Curr Sports Med Rep. 2003;2:239-242.
46. Gore CJ, McSharry PE, Hewitt AJ, et al. Preparation for football competition at moderate to high altitude. Scand J Med Sci Sports. 2008;18: 85-95.
47. Meehan RT. Immune suppression at high altitude. Ann Emerg Med. 1987;16:974-979.
48. Rigel DS, Rigel EG, Rigel AC. Effects of altitude and latitude on ambient UVB radiation. J Am Acad Dermatol. 1999;40:114-116.
49. Wilber RL. Application of altitude/hypoxic training by elite athletes. Med Sci Sports Exerc. 2007;39:1610-1624.
50. Hug DH, Hunter JK, Dunkerson DD. Malnutrition, urocanic acid, and sun may interact to suppress immunity in sojourners to high altitude. Aviat Space Environ Med. 2001;72:136-145.
51. Nieman DC. Immune response to heavy exertion. J Appl Physiol. 1997; 82:1385-1394.
52. Nieman DC, Pedersen BK. Exercise and immune function. Recent developments. Sports Med. 1999;27:73-80.
53. Nieman DC. Special feature for the Olympics: effects of exercise on the immune system: exercise effects on systemic immunity. Immunol Cell Biol. 2000;78:496-501.
54. Gleeson M, Nieman DC, Pedersen BK. Exercise, nutrition and immune function. J Sports Sci. 2004;22:115-125.
55. Duthie MS, Kimber I, Norval M. The effects of ultraviolet radiation on the human immune system. Br J Dermatol. 1999;140:995-1009.
56. Pipe AL. International travel and the elite athlete. Clin J Sport Med. 2011;21:62-66.
57. Millet GP, Roels B, Schmitt L, et al. Combining hypoxic methods for peak performance. Sports Med. 2010;40:1-25.
58. Hetzler RK, Stickley CD, Kimura IF, et al. The effect of dynamic intermittent hypoxic conditioning on arterial oxygen saturation. Wilderness Environ Med. 2009;20:26-32.
59. Levine BD, Stray-Gundersen J, Mehta RD. Effect of altitude on football performance. Scand J Med Sci Sports. 2008;18(S1):76-84.
60. Koehle MS, Sheel AW, Milsom WK, et al. Two patterns of daily hypoxic exposure and their effects on measures of chemosensitivity in humans. J Appl Physiol. 2007;103:1973-1978.
61. Townsend NE, Gore CJ, Hahn AG, et al. Hypoxic ventilatory response is correlated with increased submaximal exercise ventilation after live high, train low. Eur J Appl Physiol. 2005;94:207-215.
62. Katayama K, Sato Y, Morotome Y, et al. Intermittent hypoxia increases ventilation and Sa(O2) during hypoxic exercise and hypoxic chemosensitivity. J Appl Physiol. 2001;90:1431-1440.
63. Katayama K, Sato Y, Shima N, et al. Enhanced chemosensitivity after intermittent hypoxic exposure does not affect exercise ventilation at sea level. Eur J Appl Physiol. 2002;87:187-191.
64. Debevec T, Amon M, Keramidas ME, et al. Normoxic and hypoxic performance following 4 weeks of normobaric hypoxic training. Aviat Space Environ Med. 2010;81:387-393.
65. Faulhaber M, Gatterer H, Haider T, et al. Intermittent hypoxia does not affect endurance performance at moderate altitude in well-trained athletes. J Sports Sci. 2010;28:513-519.
66. Rodriguez FA, Ventura JL, Casas M, et al. Erythropoietin acute reaction and haematological adaptations to short, intermittent hypobaric hypoxia. Eur J Appl Physiol. 2000;82:170-177.
67. Julian CG, Gore CJ, Wilber RL, et al. Intermittent normobaric hypoxia does not alter performance or erythropoietic markers in highly trained distance runners. J Appl Physiol. 2004;96:1800-1807.
68. Lundby C, Nielsen TK, Dela F, et al. The influence of intermittent altitude exposure to 4100 m on exercise capacity and blood variables. Scand J Med Sci Sports. 2005;15:182-187.
69. Dempsey JA. Challenges for future research in exercise physiology as applied to the respiratory system. Exerc Sport Sci Rev. 2006;34:92-98.
70. Castellani JW, Muza SR, Cheuvront SN, et al. Effect of hypohydration and altitude exposure on aerobic exercise performance and acute mountain sickness. J Appl Physiol. 2010;109:1792-1800.
71. Bergeron MF, Bahr R, Bärtsch P, et al. International Olympic Committee consensus statement on thermoregulatory and altitude challenges for high-level athletes. Br J Sports Med. 2012;46:770-779.
72. Luks AM. Which medications are safe and effective for improving sleep at high altitude? High Alt Med Biol. 2008;9:195-198.
73. Stepanski EJ, Wyatt JK. Use of sleep hygiene in the treatment of insomnia. Sleep Med Rev. 2003;7:215-225.
74. Reilly T, Atkinson G, Edwards B, et al. Coping with jet-lag: a position statement for the European College of Sport Science. Eur J Sport Sci. 2007;7:1-7.
75. Nickol AH, Leverment J, Richards P, et al. Temazepam at high altitude reduces periodic breathing without impairing next-day performance: a randomized cross-over double-blind study. J Sleep Res. 2006;15:445-454.
76. Beaumont M, Batejat D, Pierard C, et al. Zaleplon and zolpidem objectively alleviate sleep disturbances in mountaineers at a 3,613 meter altitude. Sleep. 2007;30:1527-1533.
77. Hackett PH, Roach RC, Harrison GL, et al. Respiratory stimulants and sleep periodic breathing at high altitude. Almitrine versus acetazolamide. Am Rev Respir Dis. 1987;135:896-898.
78. Fischer R, Lang SM, LeitlM, et al. Theophylline and acetazolamide reduce sleep-disordered breathing at high altitude. Eur Respir J. 2004;23:47-52.